Icariside Ⅱ Attenuates Bleomycin-Induced Pulmonary Fibrosis by Modulating Macrophage Polarization
Lingling Deng,Boshu Ouyang,Hanlin Shi,Fangyong Yang,Shihuan Li,Cong Xie,Wenjing Du,Lingli Hu,Ying Wei,Jingcheng Dong
DOI: https://doi.org/10.1016/j.jep.2023.116810
IF: 5.195
2023-01-01
Journal of Ethnopharmacology
Abstract:Ethnopharmacological relevance: Numerous studies have provided evidence supporting the significant roles of icariin, in the prevention of multiple chronic diseases like diabetes, liver fibrosis, cardiac fibrosis, renal fibrosis, and pulmonary fibrosis. In particular, Icariside II (ISE II), a prominent flavonoid glycoside derived from Epimedium brevicornum Maxim, the principal metabolite of icariin, has demonstrated noteworthy anti-inflammatory and anti-oxidant properties, along with its ability to protect against lung remodeling. However, the research exploring ISE II's application in treating pulmonary fibrosis remains limited. Aim of the study: The aim of this study was to assess the therapeutic efficacy of ISE II in models of pulmonary fibrosis, while also investigating its potential mechanisms of action in cell signaling pathways. Materials and methods: An in vitro model of pulmonary fibrosis was established by treating NIH-3T3 cells with transforming growth factor-& beta;1 (TGF-& beta;1). Western blot, RT-qPCR, and scratch test were performed to assess the effect of ISE II. In addition, a murine model of pulmonary fibrosis was induced by intratracheal instillation of bleomycin, and the therapeutic effect of ISE II was tested by orally administering ISE II at a dose of 10 mg/kg. Three weeks later, lung function, micro-CT, hydroxyproline content, pathological staining, and cytokines detection of BALF or serum were used to assess the anti-fibrosis effects of ISE II. Next, immunofluorescence staining, flow cytometry, and in vivo transcriptomics were used to investigate the underlying mechanisms of action. Results: Our data revealed a significant inhibitory effect of ISE II on the upregulation of & alpha;-smooth muscle actin (& alpha;-SMA) and collagen production induced by TGF-& beta;1 in fibroblasts. Meanwhile, ISE II exerted a therapeutic effect against bleomycin-induced pulmonary fibrosis in mice by improving lung function, decreasing collagen deposition, and reducing the expression of interleukin (IL)-1 & beta;, tumor necrosis factor & alpha; (TNF-& alpha;), TGF-& beta;1 and plateletderived growth factor (PDGF) in serum and bronchoalveolar lavage fluid (BALF). Additionally, ISE II treatment effectively attenuated the infiltration of M2 macrophages, concurrently downregulating the expression level of M2 marker genes, such as CD206, arginase-1(Arg-1), and Chitinase-Like Protein 3 (YM-1). Importantly, we observed a statistically significant reduction in the M2 phenotype of interstitial macrophages (IMs). However, the impact of ISE II on the M2 polarization of alveolar macrophages (AMs) did not reach statistical significance. Lastly, transcriptome sequencing results suggested that the anti-pulmonary fibrosis effects of ISE II may be mediated by the suppression of the WNT/& beta;-catenin signaling pathway, which modulated M2 polarization in macrophages and contributed to the amelioration of pulmonary fibrosis. By immunohistochemical analysis, it was verified that ISE II treatment dramatically inhibited the activation of & beta;-catenin in fibrosis murine. Conclusion: Our findings indicated that ISE II exerted anti-fibrotic effects by inhibiting pro-fibrotic macrophage polarization. The underlying mechanism of action might be mediated by modulating the WNT/& beta;-catenin signaling pathway to inhibit the M2 program in IMs.